Log in to search using one of your social media accounts:


Performance of 4 Immunohistochemical Phosphohistone H3 Antibodies for Marking Mitotic Figures in Breast Cancer

Background: Phosphohistone H3 (PHH3) has been suggested to facilitate and improve mitotic activity assessment in breast cancer and other tumor entities, but the reliability of respective immunohistochemical antibodies has not yet been compared for routine purposes. Our aim was to test the performance of 4 different PHH3 antibodies on a series of highly proliferating breast cancers with good preservation of morphology. Methods: Four commercially available PHH3 antibodies were tested on 9 grade 3 invasive breast cancers processed in the same batch. We analyzed the number of antibody stained and nonstained mitotic figures as well as the total of cells observed in 10 high power fields per tumor to calculate sensitivity, specificity, and accuracy of the respective antibodies for staining mitotic figures, taking morphologically defined mitotic figures as gold standard. Results: Sensitivity, specificity, and accuracy of the respective PHH3 antibodies for staining mitotic figures were 54.51%, 99.98%, and 98.79% for Cell Marque, 87.48%, 67.62%, and 67.47% for Epitomics, 98.62%, 99.73%, and 99.49% for Merck 06-570, and 99.74%, 99.52%, and 99.51% for Merck 09-797, respectively. Sensitivity was lowest for telophase. In statistical analysis, the Cell Marque antibody demonstrated significantly lower sensitivity and Epitomics substantially lower sensitivity and specificity than Merck 06-570 and Merck 09-797 antibodies (P
Source: Applied Immunohistochemistry and Molecular Morphology - Category: Chemistry Tags: Research Articles Source Type: research

Related Links:

Most women tend to overestimate their risk of breast cancer, according to research...Read more on AuntMinnie.comRelated Reading: At-risk women not receiving breast MRI scans Mammo recalls don't keep women from other tests Most women prefer annual breast cancer screening Women still value mammography's benefits over 'harms' Simple interventions reduce mammography recall rates
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Does aspirin or ibuprofen reduce risk of HER2+ breast cancer?Breast Cancer Research
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
ConclusionsAlthough total nonvertebral fracture risk was higher among AI users, differences in hip fractures were not significant in a large population-based cohort of older women.Implications for Cancer SurvivorsUse of aromatase inhibitors by older women is associated with high risk for nonvertebral fracture that is increased compared with use of tamoxifen. Fracture risk should be assessed among patients taking these medications.
Source: Journal of Cancer Survivorship - Category: Cancer & Oncology Source Type: research
Publication date: Available online 14 December 2017 Source:The Journal of Steroid Biochemistry and Molecular Biology Author(s): René Maltais, Alexandre Trottier, Jenny Roy, Diana Ayan, Nicolas Bertrand, Donald Poirier The development of a covalent inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) is a promising approach for the treatment of hormone-dependent breast cancer and endometriosis. After reporting the steroid derivative PBRM as a first potent covalent inhibitor of 17β-HSD1 without estrogenic activity, we are now interested in studying its pharmaceutical behavior. The metabolism...
Source: The Journal of Steroid Biochemistry and Molecular Biology - Category: Biochemistry Source Type: research
AbstractThe identification of patients at risk for breast cancer by genetic testing has proven to reduce breast cancer mortality. In 2010, due to a lack of systematization in hereditary cancer assistance in our center, we implemented a multidisciplinary Heredofamilial Cancer Unit (HFCU). We analyze if the HFCU improved the rates of referrals and preventive management of breast cancer patients with genetic risk. We retrospectively compared family history records, referrals of high-risk patients to genetic counseling, and detection and management of patients with BRCA1/2 mutations in two cohorts of breast cancer patients dia...
Source: Journal of Genetic Counseling - Category: Genetics & Stem Cells Source Type: research
BOSTON (CBS) – More than 40% of women in the United States have dense breasts which can make it hard to find small cancers on a mammogram, but researchers are testing a new technology that could help. It is a 3-dimensional ultrasound called SoftVue. During the exam, the patient lies on her stomach, and her breast is placed into a warm water bath. In two to four minutes, the machine creates a 3D image using sound waves. SoftVue exam (WBZ-TV) There is no radiation and no compression of the breast. While SoftVue probably would not replace a woman’s annual mammogram, it might be used in conjunction with mammography...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Breast Cancer Health Local News Syndicated Local Dr. Mallika Marshall HealthWatch Local TV Source Type: news
Smith &Nephew has begun selling a handheld imaging device that can detect bacteria in hard-to-heal wounds and instantly measure wound surface area. MolecuLight i:X is already available in Canada, where its inventor stumbled across the idea for the device. Ralph DaCosta, MD, now a principal investigator at Princess Margaret Cancer Center in Toronto, was a PhD student researching fluorescent imaging of gastrointestinal cancer in 2007. The big, expensive device he was using didn’t produce any green images, which would have indicated cancer, but a red image that he couldn’t identify. DaCosta took a photo of th...
Source: MDDI - Category: Medical Devices Authors: Tags: Imaging Source Type: news
This article is protected by copyright. All rights reserved
Source: Journal of Cellular Physiology - Category: Cytology Authors: Tags: REVIEW ARTICLE Source Type: research
Conditions:   Breast Cancer;   Chemotherapy;   Endocrine Breast Diseases Interventions:   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Goserelin acetate;   Drug: Tamoxifen;   Drug: Letrozole Sponsor:   Zhiyong Yu Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Lymphedema Interventions:   Other: local distribution points association;   Other: local-distal points association;   Other: exercise with compression sleeve Sponsors:   Tianjin University of Traditional Chinese Medicine;   National Basic Research Program, China;   Tianjin Medical University Cancer Institute and Hospital;   The Second Affiliated Hospital of Baotou Medical College;   Henan Provincial Cancer Hospital;   Qilu Hospital of ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemistry | Merck | Statistics